News

Invitation to presentation of RaySearch’s interim report for the first quarter of 2025Invitation to presentation of RaySearch’s interim report for the first quarter of 2025

Invitation to presentation of RaySearch’s interim report for the first quarter of 2025

STOCKHOLM, April 25, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report…

2 days ago
Avantor® Announces CEO TransitionAvantor® Announces CEO Transition

Avantor® Announces CEO Transition

Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global…

2 days ago
Avantor® Announces CEO TransitionAvantor® Announces CEO Transition

Avantor® Announces CEO Transition

Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global…

2 days ago
Avantor® Reports First Quarter 2025 ResultsAvantor® Reports First Quarter 2025 Results

Avantor® Reports First Quarter 2025 Results

Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5…

2 days ago
Avantor® Reports First Quarter 2025 ResultsAvantor® Reports First Quarter 2025 Results

Avantor® Reports First Quarter 2025 Results

Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5…

2 days ago
Odense University Hospital selects RayStationOdense University Hospital selects RayStation

Odense University Hospital selects RayStation

STOCKHOLM, April 25, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that Odense University Hospital (OUH), which is part of…

2 days ago
Tevogen Bio Announces 2025 Annual MeetingTevogen Bio Announces 2025 Annual Meeting

Tevogen Bio Announces 2025 Annual Meeting

WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced…

2 days ago
Tevogen Bio Announces 2025 Annual MeetingTevogen Bio Announces 2025 Annual Meeting

Tevogen Bio Announces 2025 Annual Meeting

WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced…

2 days ago
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADCPyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential…

2 days ago
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADCPyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential…

2 days ago